MediciNova Inc Asset Resilience Ratio
MediciNova Inc asset resilience ratio. MediciNova Inc (MNOV) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of MediciNova Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MediciNova Inc (2003–2023)
Asset resilience ratio of MediciNova Inc from 2003 to 2023. This chart shows how MediciNova Inc's Asset Resilience Ratio has changed over time. Read how much debt does MediciNova Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MediciNova Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MediciNova Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: MediciNova Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
MediciNova Inc Industry Peers by Asset Resilience Ratio
Compare MediciNova Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
MediciNova Inc Asset Resilience Ratio by Year (2003–2023)
MediciNova Inc asset resilience ratio by year from 2003 to 2023. The table below shows the annual Asset Resilience Ratio data for MediciNova Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $66.27 Million | -- |
| 2022-12-31 | 53.92% | $39.98 Million | $74.15 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $87.41 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $43.42 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $39.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.91 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $27.27 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $29.55 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $19.57 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $30.79 Million | -- |
| 2010-12-31 | 0.86% | $623.75K | $72.93 Million | -27.57pp |
| 2009-12-31 | 28.42% | $26.81 Million | $94.33 Million | -41.89pp |
| 2007-12-31 | 70.31% | $51.86 Million | $73.75 Million | -15.46pp |
| 2006-12-31 | 85.77% | $95.72 Million | $111.59 Million | +14.83pp |
| 2005-12-31 | 70.95% | $101.02 Million | $142.39 Million | +48.63pp |
| 2004-12-31 | 22.32% | $12.00 Million | $53.77 Million | +0.12pp |
| 2003-12-31 | 22.20% | $1.25 Million | $5.63 Million | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more